Access the full text.
Sign up today, get DeepDyve free for 14 days.
Li Wang, O. Baser, L. Kutikova, J. Page, R. Barron (2014)
The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trialsSupportive Care in Cancer, 23
G. Boeru, I. Milanov, F. Robertis, W. Kozubski, M. Lang, S. Rojas-Farreras, M. Tomlinson (2013)
ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European studyMedical Devices (Auckland, N.Z.), 6
E. Wolff-Holz, Klara Tiitso, C. Vleminckx, M. Weise (2019)
Evolution of the EU Biosimilar Framework: Past and FutureBiodrugs, 33
(Arad N, Staton E, Hamilton Lopez M, et al. Realizing the benefits of biosimilars: overcoming rebate walls. https://healthpolicy.duke.edu/sites/default/files/2022-03/Biosimilars%20-%20Overcoming%20Rebate%20Walls.pdf. Accessed June 9, 2022.)
Arad N, Staton E, Hamilton Lopez M, et al. Realizing the benefits of biosimilars: overcoming rebate walls. https://healthpolicy.duke.edu/sites/default/files/2022-03/Biosimilars%20-%20Overcoming%20Rebate%20Walls.pdf. Accessed June 9, 2022.Arad N, Staton E, Hamilton Lopez M, et al. Realizing the benefits of biosimilars: overcoming rebate walls. https://healthpolicy.duke.edu/sites/default/files/2022-03/Biosimilars%20-%20Overcoming%20Rebate%20Walls.pdf. Accessed June 9, 2022., Arad N, Staton E, Hamilton Lopez M, et al. Realizing the benefits of biosimilars: overcoming rebate walls. https://healthpolicy.duke.edu/sites/default/files/2022-03/Biosimilars%20-%20Overcoming%20Rebate%20Walls.pdf. Accessed June 9, 2022.
A. McBride, A. Krendyukov, N. Mathieson, K. Campbell, S. Balu, M. Natek, K. MacDonald, I. Abraham (2020)
Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphomaJournal of Medical Economics, 23
P. Cornes, P. Gascón, A. Vulto, M. Aapro (2020)
Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables CureBiodrugs, 34
K. MacDonald, A. McBride, N. Alrawashdh, I. Abraham (2020)
Cost-efficiency and expanded access of prophylaxis for chemotherapy-induced (febrile) neutropenia: economic simulation analysis for the US of conversion from reference pegfilgrastim to biosimilar pegfilgrastim-cbqvJournal of Medical Economics, 23
J. Klastersky, J. Naurois, K. Rolston, B. Rapoport, G. Maschmeyer, M. Aapro, J. Herrstedt (2010)
Management of febrile neutropaenia: ESMO Clinical Practice Guidelines.Annals of oncology : official journal of the European Society for Medical Oncology, 27 suppl 5
(US Food and Drug Administration. Guidance for Industry. Scientific considerations in demonstrating biosimilarity to a reference product. 2015. https://www.fda.gov/media/82647/download. Accessed June 9, 2022.)
US Food and Drug Administration. Guidance for Industry. Scientific considerations in demonstrating biosimilarity to a reference product. 2015. https://www.fda.gov/media/82647/download. Accessed June 9, 2022.US Food and Drug Administration. Guidance for Industry. Scientific considerations in demonstrating biosimilarity to a reference product. 2015. https://www.fda.gov/media/82647/download. Accessed June 9, 2022., US Food and Drug Administration. Guidance for Industry. Scientific considerations in demonstrating biosimilarity to a reference product. 2015. https://www.fda.gov/media/82647/download. Accessed June 9, 2022.
(2010)
sur - vivors living in the United States
A. Jindal, J. Kover, Vanja Raduka, T. O'brien (2018)
Incidence of Neutropenic Fever at a Safety Net Hospital in Cancer Chemotherapy Patients Receiving Prophylactic Pegfilgrastim Manual Injection Compared to the on-Body Auto-InjectorBlood
L. Gordon, K. Merollini, A. Lowe, R. Chan (2017)
A Systematic Review of Financial Toxicity Among Cancer Survivors: We Can’t Pay the Co-PayThe Patient - Patient-Centered Outcomes Research, 10
J. Webster, Robert Smith, D. Wieland, J. Verniero, Jeffrey Scott (2020)
Cost savings of biosimilar pegfilgrastim in a Medicare OCM population.Journal of Clinical Oncology, 38
Caroline Townley, Courtney Porter, Nicole McMullen (2018)
Comparing Grade 4 Neutropenia Associated with Pegfilgrastim Administered via the Onpro Device versus Manual Injection with a Prefilled Syringe
E. Tai, G. Guy, A. Dunbar, L. Richardson (2017)
Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012.Journal of oncology practice, 13 6
(IQVIA Institute for Human Data Science. Biosimilars in the United States 2020–2024. 2020. https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2020-2024. Accessed June 9, 2022.)
IQVIA Institute for Human Data Science. Biosimilars in the United States 2020–2024. 2020. https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2020-2024. Accessed June 9, 2022.IQVIA Institute for Human Data Science. Biosimilars in the United States 2020–2024. 2020. https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2020-2024. Accessed June 9, 2022., IQVIA Institute for Human Data Science. Biosimilars in the United States 2020–2024. 2020. https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2020-2024. Accessed June 9, 2022.
A. Naeim, H. Henk, L. Becker, V. Chia, Sejal Badre, Xiaoyan Li, R. Deeter (2013)
Pegfilgrastim prophylaxis is associated with a lower risk of hospitalization of cancer patients than filgrastim prophylaxis: a retrospective United States claims analysis of granulocyte colony-stimulating factors (G-CSF)BMC Cancer, 13
D. Weycker, M. Bensink, A. Lonshteyn, Robin Doroff, D. Chandler (2017)
Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015Current Medical Research and Opinion, 33
P. Gascón, M. Aapro, H. Ludwig, C. Bokemeyer, M. Boccadoro, M. Turner, K. Denhaerynck, K. MacDonald, I. Abraham (2016)
Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)Supportive Care in Cancer, 24
A. McBride, K. MacDonald, I. Abraham (2020)
Simulation modeling of budget-neutral expanded access to antineoplastic therapy from cost-savings derived from conversion to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) in early-stage breast cancer.Journal of Clinical Oncology, 38
National Comprehensive Cancer Network. NCCN practice guidelines in oncology
John Eckstrom, Trace Bartels, I. Abraham, Hitendra Patel, E. Elquza, A. Scott, S. Malangone, J. Hollings, A. McBride (2018)
A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRISupportive Care in Cancer, 27
L. Mahler, R. Diblasi, Á.N. Pérez, J. Gaspard, D. McCauley (2017)
On‐Body Injector: An administration device for pegfilgrastimClinical Journal of Oncology Nursing, 21
A. Pagels, B. Hylander (2012)
Anaemia management in chronic kidney disease patientsJournal of Renal Nursing, 4
(US Food and Drug Administration. Biosimilar product information. 2020. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information. Accessed June 9, 2022.)
US Food and Drug Administration. Biosimilar product information. 2020. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information. Accessed June 9, 2022.US Food and Drug Administration. Biosimilar product information. 2020. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information. Accessed June 9, 2022., US Food and Drug Administration. Biosimilar product information. 2020. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information. Accessed June 9, 2022.
Biosimilars in the EU. Information Guide for Healthcare Professionals
Amanda Gerberich, Mark Attilio, Alison Svoboda (2020)
Revisiting same day administration of pegfilgrastim in the age of biosimilars: A review of literatureJournal of Oncology Pharmacy Practice, 26
P. Cornes, P. Gascón, S. Chan, K. Hameed, Catherine Mitchell, P. Field, M. Latymer, Luiz Arantes (2018)
Systematic Review and Meta-analysis of Short- versus Long-Acting Granulocyte Colony-Stimulating Factors for Reduction of Chemotherapy-Induced Febrile NeutropeniaAdvances in Therapy, 35
P. Gascón, H. Tesch, K. Verpoort, M. Rosati, N. Salesi, S. Agrawal, N. Wilking, H. Barker, M. Muenzberg, M. Turner (2013)
Clinical experience with Zarzio® in Europe: what have we learned?Supportive Care in Cancer, 21
(2022)
Realizing the benefits of biosimilars: overcoming rebate walls. https://healthpolicy.duke.edu/sites/default/files/ 2022-03/Biosimilars%20-%20Overcoming% 20Rebate%20Walls.pdf
(Amgen Inc. Amgen 2021 biosimilar trend report. 2021. https://www.amgenbiosimilars.com/commitment/-/media/Themes/Amgen/amgenbiosimilars-com/Amgenbiosimilars-com/pdf/USA-CBU-80962_Amgen-2021-Biosimilar-Trends-Report.pdf Accessed June 9, 2022.)
Amgen Inc. Amgen 2021 biosimilar trend report. 2021. https://www.amgenbiosimilars.com/commitment/-/media/Themes/Amgen/amgenbiosimilars-com/Amgenbiosimilars-com/pdf/USA-CBU-80962_Amgen-2021-Biosimilar-Trends-Report.pdf Accessed June 9, 2022.Amgen Inc. Amgen 2021 biosimilar trend report. 2021. https://www.amgenbiosimilars.com/commitment/-/media/Themes/Amgen/amgenbiosimilars-com/Amgenbiosimilars-com/pdf/USA-CBU-80962_Amgen-2021-Biosimilar-Trends-Report.pdf Accessed June 9, 2022., Amgen Inc. Amgen 2021 biosimilar trend report. 2021. https://www.amgenbiosimilars.com/commitment/-/media/Themes/Amgen/amgenbiosimilars-com/Amgenbiosimilars-com/pdf/USA-CBU-80962_Amgen-2021-Biosimilar-Trends-Report.pdf Accessed June 9, 2022.
H. Al-Shamsi, W. Alhazzani, Ahmad Alhuraiji, E. Coomes, R. Chemaly, Meshari Almuhanna, R. Wolff, Ibrahim Nuhad, M. Chua, S. Hotte, B. Meyers, T. Elfiki, G. Curigliano, C. Eng, A. Grothey, C. Xie (2020)
A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID‐19) Pandemic: An International Collaborative GroupThe Oncologist, 25
L. Roskos, Peggy Lum, P. Lockbaum, G. Schwab, Bing‐Bing Yang (2006)
Pharmacokinetic/Pharmacodynamic Modeling of Pegfilgrastim in Healthy SubjectsThe Journal of Clinical Pharmacology, 46
Guidance for Industry. Scientific considerations in demonstrating biosimilarity to a reference product
D. Weycker, J. Hackett, J. Edelsberg, G. Oster, A. Glass (2006)
Are Shorter Courses of Filgrastim Prophylaxis Associated with Increased Risk of Hospitalization?Annals of Pharmacotherapy, 40
N. Alrawashdh, Jamie Vraney, Briana Choi, A. Almutairi, I. Abraham, A. McBride (2022)
Retrospective evaluation of safety and effectiveness of same-day pegfilgrastim in patients with lung cancer.Future oncology
Barbara Desanto (2021)
US Food and Drug AdministrationThe Palgrave Encyclopedia of Interest Groups, Lobbying and Public Affairs
Daniel Oberski (2020)
Human Data SciencePatterns, 1
(European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf. Accessed June 9, 2022.)
European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf. Accessed June 9, 2022.European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf. Accessed June 9, 2022., European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf. Accessed June 9, 2022.
C. Blank (2019)
IQVIA Institute for Human Data Science Releases 2018 Medicine Use and Spending Results
R. Ohsfeldt, C. Choong, Patrick Collam, H. Abedtash, K. Kelton, R. Burge (2021)
Inpatient Hospital Costs for COVID-19 Patients in the United StatesAdvances in Therapy, 38
M. Aapro, J. Bohlius, D. Cameron, L. Lago, J. Donnelly, N. Kearney, G. Lyman, R. Pettengell, V. Tjan-Heijnen, J. Walewski, D. Weber, C. Zielinski (2011)
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.European journal of cancer, 47 1
(2011)
GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS CONTAINING BIOTECHNOLOGY-DERIVED PROTEINS AS ACTIVE SUBSTANCE: NON-CLINICAL AND CLINICAL ISSUES
(Memorial Sloan Kettering Cancer Center. Giving yourself an injection of filgrastim (Neupogen®) or Pegfilgrastim (Neulasta®) with a prefilled syringe. 2019. https://www.mskcc.org/cancer-care/patient-education/directions-giving-injection-below-skin-neupogen-filgrastim-neulasta-pegfilgrastim-pre-filled-syringe. Accessed June 9, 2022.)
Memorial Sloan Kettering Cancer Center. Giving yourself an injection of filgrastim (Neupogen®) or Pegfilgrastim (Neulasta®) with a prefilled syringe. 2019. https://www.mskcc.org/cancer-care/patient-education/directions-giving-injection-below-skin-neupogen-filgrastim-neulasta-pegfilgrastim-pre-filled-syringe. Accessed June 9, 2022.Memorial Sloan Kettering Cancer Center. Giving yourself an injection of filgrastim (Neupogen®) or Pegfilgrastim (Neulasta®) with a prefilled syringe. 2019. https://www.mskcc.org/cancer-care/patient-education/directions-giving-injection-below-skin-neupogen-filgrastim-neulasta-pegfilgrastim-pre-filled-syringe. Accessed June 9, 2022., Memorial Sloan Kettering Cancer Center. Giving yourself an injection of filgrastim (Neupogen®) or Pegfilgrastim (Neulasta®) with a prefilled syringe. 2019. https://www.mskcc.org/cancer-care/patient-education/directions-giving-injection-below-skin-neupogen-filgrastim-neulasta-pegfilgrastim-pre-filled-syringe. Accessed June 9, 2022.
J. Diggle (2014)
How to help patients achieve correct self-injection techniquePractice Nursing, 25
A. McBride, K. MacDonald, I. Abraham (2020)
Simulation modeling of cost-savings from conversion of pegfilgrastim to biosimilar pegfilgrastim-cbqv for the prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) and expanded access to biosimilar prophylaxis.Journal of Clinical Oncology, 38
D. Weycker, M. Bensink, A. Lonshteyn, Robin Doroff, D. Chandler (2019)
Use of colony-stimulating factor primary prophylaxis and incidence of febrile neutropenia from 2010 to 2016: a longitudinal assessmentCurrent Medical Research and Opinion, 35
(2018)
UDENYCA TM (pegfilgrastim-cbqv) injection, for subcutaneous use. Redwood City
Giving yourself an injection of filgrastim (NeupogenÒ) or Pegfilgrastim (Neulasta Ò ) with a prefilled syringe
T. Arvedson, J. O'kelly, Bing‐Bing Yang (2015)
Design Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating FactorBiodrugs, 29
K. Weaver, J. Rowland, Keith Bellizzi, N. Aziz (2010)
Forgoing medical care because of costCancer, 116
Neal Meropol, Langdon Miller, Edward Korn, Leonard Braitman, Mary MacDermott, Lynn Schuchter (1992)
Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy.Journal of the National Cancer Institute, 84 15
G. French, Mary Hulse, D. Nguyen, Katharine Sobotka, Kaitlyn Webster, Josh Corman, Brago Aboagye-Nyame, Marcelle Dion, Moira Johnson, Benjamin Zalinger, M. Ewing (2021)
Impact of Hospital Strain on Excess Deaths During the COVID-19 Pandemic — United States, July 2020–July 2021Morbidity and Mortality Weekly Report, 70
(Xcenda and the Biosimilars Forum. Biosimilars Have Significantly Lowered Prices of All Biologics. 2021. https://biosimforum.wpengine.com/wp-content/uploads/Xcenda-ASP-One-Pager.pdf. Accessed June 9, 2022.)
Xcenda and the Biosimilars Forum. Biosimilars Have Significantly Lowered Prices of All Biologics. 2021. https://biosimforum.wpengine.com/wp-content/uploads/Xcenda-ASP-One-Pager.pdf. Accessed June 9, 2022.Xcenda and the Biosimilars Forum. Biosimilars Have Significantly Lowered Prices of All Biologics. 2021. https://biosimforum.wpengine.com/wp-content/uploads/Xcenda-ASP-One-Pager.pdf. Accessed June 9, 2022., Xcenda and the Biosimilars Forum. Biosimilars Have Significantly Lowered Prices of All Biologics. 2021. https://biosimforum.wpengine.com/wp-content/uploads/Xcenda-ASP-One-Pager.pdf. Accessed June 9, 2022.
Bing‐Bing Yang, P. Morrow, Xikun Wu, M. Moxness, D. Padhi (2015)
Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringeCancer Chemotherapy and Pharmacology, 75
(National Comprehensive Cancer Network. NCCN practice guidelines in oncology. Hematopoietic Growth Factors. Version 1.2022. 2021. Accessed 02/17/2022.)
National Comprehensive Cancer Network. NCCN practice guidelines in oncology. Hematopoietic Growth Factors. Version 1.2022. 2021. Accessed 02/17/2022.National Comprehensive Cancer Network. NCCN practice guidelines in oncology. Hematopoietic Growth Factors. Version 1.2022. 2021. Accessed 02/17/2022., National Comprehensive Cancer Network. NCCN practice guidelines in oncology. Hematopoietic Growth Factors. Version 1.2022. 2021. Accessed 02/17/2022.
A. Hauber, B. Mange, M. Price, D. Wolin, M. Bensink, J. Kaye, D. Chandler (2017)
Administration options for pegfilgrastim prophylaxis: patient and physician preferences from a cross-sectional surveySupportive Care in Cancer, 26
N. Alrawashdh, A. McBride, Christopher Lee, Reem Diri, Alaa Bagalagel, Hussain Bakhsh, H. Babiker, K. MacDonald, I. Abraham (2018)
Outcomes of pegfilgrastim (PFG) administration on the same day vs the day after chemotherapy (CTX) in the prophylaxis of chemotherapy-induced (Febrile) neutropenia (CIN/FN): Systematic review and meta-analysis.Journal of Clinical Oncology, 36
Reem Diri, Reem Diri, A. McBride, Christopher Lee, Alaa Bagalagel, Alaa Bagalagel, Hussain Bakhsh, Hussain Bakhsh, D. Persky, K. MacDonald, Jennifer Martin, I. Abraham (2015)
Efficacy of Same-Day Vs. Next-Day Pegfilgrastim for the Prevention of Chemotherapy-Induced (Febrile) Neutropenia (CIN/FN): A Meta-AnalysisBlood, 126
A. Kaye, Chikezie Okeagu, Alex Pham, R.A.K. Silva, Joshua Hurley, B. Arron, Noeen Sarfraz, H. Lee, G. Ghali, Jack Gamble, Henry Liu, R. Urman, E. Cornett (2020)
Economic impact of COVID-19 pandemic on healthcare facilities and systems: International perspectivesBest Practice & Research. Clinical Anaesthesiology, 35
P. Stuessy, F. Sanchez, M. Schober (2017)
Retrospective review of pegfilgrastim on-body injector delivery rates in a large health system.Journal of Clinical Oncology, 35
E. Rowinsky, L. Grochow, S. Sartorius, M. Bowling, S. Kaufmann, D. Peereboom, R. Donehower (1996)
Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 4
(European Medicines Agency. Biosimilars in the EU. Information Guide for Healthcare Professionals. 2019. https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed June 9, 2022.)
European Medicines Agency. Biosimilars in the EU. Information Guide for Healthcare Professionals. 2019. https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed June 9, 2022.European Medicines Agency. Biosimilars in the EU. Information Guide for Healthcare Professionals. 2019. https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed June 9, 2022., European Medicines Agency. Biosimilars in the EU. Information Guide for Healthcare Professionals. 2019. https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed June 9, 2022.
B. Rome, A. Sarpatwari (2021)
Promoting Biosimilar Competition by Revising Medicare Reimbursement Rules.JAMA network open, 4 11
Kathleen Fenn, S. Evans, R. McCorkle, M. DiGiovanna, L. Pusztai, T. Sanft, E. Hofstatter, B. Killelea, M. Knobf, D. Lannin, M. Abu-Khalaf, N. Horowitz, A. Chagpar (2014)
Impact of financial burden of cancer on survivors' quality of life.Journal of oncology practice, 10 5
Rajeshree Joshi, O. Egbuna, A. Cairns, M. Friedman, Bassam Abosaleem, M. Reiner, P. Morrow (2017)
Performance of the pegfilgrastim on-body injector as studied with placebo buffer in healthy volunteersCurrent Medical Research and Opinion, 33
(2018)
Ethnic differences in pegfilgrastim Onpro kit (on-body injector) use among cancer patients
Granulocyte colony-stimulating factor (G-CSF) biologics, such as pegfilgrastim, are a standard of care in supportive cancer treatment that are administered once per chemotherapy cycle to reduce the incidence of febrile neutropenia. The high cost of these biologics in the United States can be a limiting factor to accessing care; however, lower-cost pegfilgrastim biosimilars have been available for several years for patients requiring prophylaxis of febrile neutropenia. Different options for pegfilgrastim administration are also now available to accommodate specific patient preferences. As patients may want to minimize the risk of both neutropenia and SARS-CoV-2 infection, same-day administration is a pertinent option during the present COVID-19 pandemic. Therefore, individualized, patient-centered approaches and risk-management strategies should be considered when selecting the treatment and administration method for prophylaxis of febrile neutropenia. Three methods of administration would minimize hospital or clinic visits while also providing the prophylactic effect of G-CSF: same-day administration after chemotherapy, use of the US Food and Drug Administration–approved on-body injector delivering pegfilgrastim approximately 27 h after chemotherapy, or self-administration by the patient or caregiver > 24 h after chemotherapy. Choice of the specific administration option should be based on the patient’s specific needs, while also considering mitigating factors, such as the economic burden associated with biologic medications and the risk of COVID-19. Pegfilgrastim biosimilars can minimize the additional financial burden on patients and the health care system during this pandemic and beyond.
Oncology and Therapy – Springer Journals
Published: Dec 1, 2022
Keywords: Biologic; Biosimilar; Cost-effectiveness; Formulary management; Oncology; Pegfilgrastim; Supportive care; Utilization management
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.